AssetID: 56148430
Headline: UNCAPTIONED: US FDA Orders New Eye Risk Warnings For Ozempic And Zepbound
Caption: US FDA Orders New Eye Risk Warnings For Ozempic And Zepbound. The US Food and Drug Administration has ordered new safety warnings for popular weight-loss and diabetes drugs over a potential increased risk of serious eye damage. The requirement applies to GLP-1 medications, including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound. The warnings concern non-arteritic anterior ischemic optic neuropathy, known as NAION, which can cause sudden, painless vision loss and potentially permanent damage. The condition occurs when blood flow to the optic nerve is reduced, although its underlying causes remain incompletely understood. The FDA reviewed clinical trials, animal research and reports from patients after the drugs reached the market before requiring updated safety labels. Novo Nordisk said the available evidence did not establish a direct causal link, while Eli Lilly said it was reviewing the FDA's findings. European regulators estimated NAION could affect one in 10,000 semaglutide users, while a 2025 study found the risk more than doubled after two years. Despite the concerns, analysts said the condition remained rare and the drugs' substantial benefits for weight management and other health conditions should support continued prescribing. Instructions: THIS VIDEO MUST NOT BE EDITED FOR LENGTH TO COMBINE WITH OTHER CONTENT
Keywords: Health & Wellbeing,US FDA,Ozempic,Zepbound,Wegovy,Mounjaro,Novo Nordisk,Eli Lilly,GLP-1 Drugs,NAION,Vision Loss,Eye Damage,Semaglutide,European Medicines Agency,Drug Safety Warnings,Geoff Meacham
PersonInImage: